CEVR offers its thoughts on CMS’s most recent round of negotiated drug prices and whether they align with value.
Commentary: Do Medicare’s IPAY 2027 negotiated drug prices reflect value for money? Peter J. Neumann, Joshua T. Cohen, Sean D. Sullivan and Feng Xie. Health Affairs Forefront.
Supplemental materials – here.
• Annotated endnotes
• Computations for commentary Exhibit 1
